Polaryx Therapeutics, Inc. Common Stock (NASDAQ:PLYX) — Market Cap & Net Worth
Market Cap & Net Worth: Polaryx Therapeutics, Inc. Common Stock (PLYX)
Polaryx Therapeutics, Inc. Common Stock (NASDAQ:PLYX) has a market capitalization of $160.49 Million ($160.49 Million) as of May 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17492 globally and #4009 in its home market, demonstrating a 5.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Polaryx Therapeutics, Inc. Common Stock's stock price $3.60 by its total outstanding shares 47343297 (47.34 Million). Analyse Polaryx Therapeutics, Inc. Common Stock (PLYX) cash conversion ratio to see how efficiently the company converts income to cash.
Polaryx Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Polaryx Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $170.44 Million to $170.44 Million (0.00% CAGR).
Polaryx Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Polaryx Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PLYX by Market Capitalization
Companies near Polaryx Therapeutics, Inc. Common Stock in the global market cap rankings as of May 26, 2026.
Key companies related to Polaryx Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.28 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #417 globally with a market cap of $65.82 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #579 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #599 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.28 Billion | $434.52 |
| #417 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $65.82 Billion | $638.88 |
| #579 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #599 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Polaryx Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Polaryx Therapeutics, Inc. Common Stock's market cap moved from $170.44 Million to $ 170.44 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $170.44 Million | -- |
End of Day Market Cap According to Different Sources
On May 25th, 2026 the market cap of Polaryx Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $160.49 Million USD |
| MoneyControl | $160.49 Million USD |
| MarketWatch | $160.49 Million USD |
| marketcap.company | $160.49 Million USD |
| Reuters | $160.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more